Literature DB >> 8526702

The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer.

C J Newschaffer1, L Penberthy, C E Desch, S M Retchin, M Whittemore.   

Abstract

BACKGROUND: Increasing age has most often been associated with less aggressive approaches to treatment of nonmetastatic breast cancer in elderly women even after controlling for stage of disease at diagnosis.
OBJECTIVE: To examine the influence of patient age on the initial treatment for breast cancer received by elderly women while controlling for the effect of patient comorbidity.
METHODS: Cancer registry records for a cohort of 2252 women aged 66 years or older who were diagnosed as having nonmetastatic, invasive breast cancer between 1984 and 1989 and identified through the Virginia Cancer Registry were linked to Medicare Provider and Reimbursement data files. Multivariate models were used to assess the effects of age and comorbidity (as measured by the International Classification of Diseases, Ninth Edition, codes recorded on Medicare claims) on initial treatment approach while adjusting for stage of disease, race, residential location, marital status, and year of diagnosis.
RESULTS: In baseline multivariable models, age was negatively associated with any surgical treatment, non-breast-conserving procedures, and radiotherapy following breast-conserving surgery. The odds of women aged 85 years and older receiving surgery were less than one third those of women aged 66 to 74 years (odds ratio, 0.31; 95% confidence interval, 0.16 to 0.60), while odds ratios across the same two age groups for nonbreast-conserving surgery and adjuvant radiotherapy were 0.55 (95% confidence interval, 33 to 92) and 0.03 (confidence interval, 0.01 to 0.13), respectively. With additional adjustment for aggregate comorbidity, odds ratio estimates in these same age-group comparisons were virtually unchanged at 0.31, 0.56, and 0.04.
CONCLUSION: Aggregate comorbidity measured by inpatient International Classification of Diseases, Ninth Edition, codes on Medicare inpatient hospital claims does not explain age-related patterns in the initial treatment of elderly patients with breast cancer.

Entities:  

Mesh:

Year:  1996        PMID: 8526702

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  32 in total

1.  The limits of tamoxifen.

Authors:  M J Kennedy
Journal:  Ir J Med Sci       Date:  2002 Jan-Mar       Impact factor: 1.568

2.  Predictors of Medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer.

Authors:  L Penberthy; S M Retchin; M K McDonald; D K McClish; C E Desch; G F Riley; T J Smith; B E Hillner; C J Newschaffer
Journal:  Health Care Manag Sci       Date:  1999-07

3.  Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.

Authors:  Arti Hurria; Anju Hurria; Kelly Brogan; Katherine S Panageas; Carol Pearce; Larry Norton; Ann Jakubowski; Jane Howard; Clifford Hudis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  The influence of aging on the early detection, diagnosis, and treatment of breast cancer.

Authors:  Marisa F Siebel; Hyman B Muss
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

5.  Factors Affecting the Postsurgical Length of Hospital Stay in Patients with Breast Cancer.

Authors:  Metehan Gümüş; Ömer Satıcı; Burak Veli Ülger; Abdullah Oğuz; Fatih Taşkesen; Sadullah Girgin
Journal:  J Breast Health       Date:  2015-07-01

6.  A population-based study on variations in the use of adjuvant systemic therapy on postmenopausal patients with early stage breast cancer.

Authors:  G Nagel; B Röhrig; H Hoyer; U Wedding; D Katenkamp
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-23       Impact factor: 4.553

7.  Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers.

Authors:  Arti Hurria; F Lennie Wong; Doojduen Villaluna; Smita Bhatia; Cathie T Chung; Joanne Mortimer; Sara Hurvitz; Arash Naeim
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

8.  Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy.

Authors:  Arti Hurria; Kelly Brogan; Katherine S Panageas; Ann Jakubowski; Marjorie Zauderer; Carol Pearce; Larry Norton; Jane Howard; Clifford Hudis
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

9.  Disparities in use of gynecologic oncologists for women with ovarian cancer in the United States.

Authors:  Shamly Austin; Michelle Y Martin; Yongin Kim; Ellen M Funkhouser; Edward E Partridge; Maria Pisu
Journal:  Health Serv Res       Date:  2012-12-03       Impact factor: 3.402

10.  Outcomes research in cancer clinical trial cooperative groups: the RTOG model.

Authors:  D W Bruner; B Movsas; A Konski; M Roach; M Bondy; C Scarintino; C Scott; W Curran
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.